- Annual NHI drug price revisions creating a harsh business environment for contrast media.
- Delays in strengthening overseas business, particularly in expanding to other ASEAN countries.
- Sales shortfalls for key products such as F-meno capsules and SULPREP.
Fuji Pharma Co., Ltd.
Greenhouse gas emissions & sustainability report data
In its 2022-10 to 2023-09 reporting, Fuji Pharma Co., Ltd. disclosed greenhouse gas emissions of 13.3K tCO2e (FY2022). By scope: Scope 1: 6.0K tCO2e (FY2022); Scope 2: 8.2K tCO2e (FY2022); Scope 3: 292.4K tCO2e (FY2022). Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
13.3K tCO2e (FY2022)
2022-10 to 2023-09
📊 Emissions by Scope (2022-10 to 2023-09)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 6.0K tCO2e (FY2022) |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 8.2K tCO2e (FY2022) |
| Scope 3 | Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.). | 292.4K tCO2e (FY2022) |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2022-10 to 2023-09 | 13.3K tCO2e (FY2022) |
| 2021-10 to 2022-09 | 12.3K tCO2 (FY2021) |
| 2020-10 to 2021-09 | 11.7K tCO₂/year |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Signed an offsite solar power purchase agreement (PPA) with the Hokuriku Electric Power Group to shift 50% of Toyama Plant electricity to renewable energy by 2030.
- Set up a solar power generation facility at OLIC's plant in Thailand, generating 1,200 MWh annually and reducing CO2 emissions.
- Reduced contracted power at Toyama Research & Development Center by 15% through demand control.
🎯 Climate & Sustainability Targets
🔜 Short-term
- Increase percentage of female employees in management positions to 30% or more by March 31, 2024.
- Increase childcare leave acquisition rate to 30% or more by March 31, 2024.
📅 Medium-term
- Shift 50% of Toyama Plant electricity to renewable energy by 2030.
- Become No.1 in women’s healthcare by the end of the current Mid-Term Business Plan (FY2024).
🔭 Long-term
- Achieve carbon neutrality by 2050.
- Become the No. 1 biosimilar manufacturer in Japan by the end of the fiscal year ending September 30, 2029.
🌱 ESG Focus Areas
Women's healthClimate changeHuman rightsEmployee well-beingSupply chain sustainability